May 2018, Volume 4, Issue 6

May 2018

Volume 4, Issue 6

This issue features a look at the hidden costs of importing lower-cost drugs, the optimal hemophilia treatment, the limits of genetic testing, and more.

Table of Contents

May 2018 Issue

Workplace Violence

Tuesday, May 1st, 2018
In our March 2018 issue, ASH Clinical News Associate Editor Alice Ma, MD, recounted an unnerving experience with a threatening patient in “Not What...

What’s in a (Drug) Name?

Tuesday, May 1st, 2018
Shakespeare claimed that a rose by any other name would smell as sweet. A medication with a confusing name, though, can cause a fatal...

May 2018 Issue

Stand Up To Cancer Funds AI Research, Damon Runyon Cancer Research Foundation Research Fellows...

Tuesday, May 1st, 2018
Remembering Barry Paw (1961-2017) Barry Paw, MD, PhD, a principal investigator and pediatric oncologist at Brigham and Women’s Hospital and Dana-Farber/Boston Children’s Cancer and Blood...

ASH Announces Partnership to Foster Genomic Research, The Hematologist Debuts Two New Departments, and...

Tuesday, May 1st, 2018
ASH Programs Promoting Advocacy and Translational Research Now Accepting Nominations Advocacy Leadership Institute The American Society of Hematology (ASH) is now accepting nominations for...

May 2018 Issue

Genetic Testing: Ready, Set … Actionable?

Tuesday, May 1st, 2018
In June 2000, President Bill Clinton announced that the international Human Genome Project and Celera Genomics had completed the initial sequencing of the human...

Exploring the Boundaries of Drug Importation

Tuesday, May 1st, 2018
Importing pharmaceuticals from other countries to access lower-cost medicines is still a relatively murky issue. Hematologist Kenneth R. Adler, MD, of Summit Medical Group MD...

Pulling Back the Curtain: Brian J. Bolwell, MD

Tuesday, May 1st, 2018
In this edition, Brian J. Bolwell, MD, talks about the pediatric leukemia patient who spurred his interest in hematology, early days in the Cleveland...

Plasma or Recombinant Products for Hemophilia?

Tuesday, May 1st, 2018
For the past half-century, plasma products have been the mainstay for the treatment of patients with hemophilia. In the 1950s, hematologists used large volumes...

May 2018 Issue

Demystifying Liquid Biopsies

Tuesday, May 1st, 2018
Tumor biopsies have long been the standard method for diagnosing, monitoring, and treating cancer and, in the era of precision medicine, molecular analyses of...

How I Treat In Brief: HCT for HIV-Related Hematologic Malignancies

Tuesday, May 1st, 2018
This month, Joseph C. Alvarnas, MD, John A. Zaia, MD, and Stephen J. Forman, MD, discuss the use of hematopoietic cell transplantation (HCT) to...

How would you manage a patient who meets morphologic, but not molecular, criteria for...

Tuesday, May 1st, 2018
This month, Olatoyosi Odenike, MD, discusses a patient with a morphologic presentation suggestive of acute promyelocytic leukemia (APL), but with a negative PML/RARA fusion...

Every Minute Counts: Time Management Tips and Tricks for New Doctors

Tuesday, May 1st, 2018
Jean Louise Koff, MD, offers time-management advice for early-career hematologists transitioning from training to faculty. Dr. Koff is an instructor of hematology and medical...

May 2018 Issue

WIB_icon

Long-Term PACE Follow-Up Confirms Ponatinib’s Benefit in CP-CML

Tuesday, May 1st, 2018
At five-year follow-up, treatment with the third-generation tyrosine kinase inhibitor (TKI) ponatinib led to deep and durable responses in patients with heavily pretreated chronic-phase...

FDA Approves Nilotinib for Frontline and Secondline Use in Pediatric CML

Tuesday, May 1st, 2018
The FDA approved nilotinib for first- and secondline use in pediatric patients (≥1 year) with Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukemia (CP-CML). Approval was...

National Academy of Medicine Launches Resource Center Addressing Physician Burnout

Tuesday, May 1st, 2018
The National Academy of Medicine (NAM) launched the Clinician Well-Being Knowledge Hub, a comprehensive repository housing resources to combat physician burnout. The Knowledge Hub...

CMS Decides Coverage Requirements for NGS-Based Testing

Tuesday, May 1st, 2018
CMS released a National Coverage Determination (NCD) on next-generation sequencing (NGS) for Medicare beneficiaries with advanced cancer. The agency determined that NGS as a...

Ivosidenib Receives Priority Review for the Treatment of Relapsed/Refractory AML

Tuesday, May 1st, 2018
The FDA granted priority review to ivosidenib for the treatment of relapsed/refractory IDH1-mutated AML. The decision was based on results from an ongoing, single-arm,...

FDA Expands Treatment Window for Blood Clot Retrieval Device

Tuesday, May 1st, 2018
The FDA cleared the use of the Trevo clot retrieval device to treat certain stroke patients up to 24 hours after symptom onset –...

Report: U.S. Health-Care Spending Projections Increase Year Over Year

Tuesday, May 1st, 2018
A new report from the U.S. Centers for Medicare and Medicaid Services (CMS) projects that health-care spending will increase 5.3 percent in 2018 –...

NIH Funding Tied to FDA Approval of 210 Drugs Since 2010

Tuesday, May 1st, 2018
A report published in Proceedings of the National Academy of Sciences found that funding from the National Institutes of Health (NIH) contributed to published...

Venetoclax Outperforms Standard Chemo-Immunotherapy in the Treatment of Relapsed/Refractory CLL

Tuesday, May 1st, 2018
Treatment with the BCL2 inhibitor venetoclax and rituximab led to deeper and more durable responses than the combination of bendamustine and rituximab in patients...

Long-Term Follow-up Comparing Conditioning Regimens for Patients With AML Undergoing HCT

Tuesday, May 1st, 2018
Nearly 10 years after allogeneic hematopoietic cell transplantation (HCT), patients with acute myeloid leukemia (AML) who received either reduced-intensity conditioning or myeloablative conditioning had...

Selinexor Plus Dexamethasone Active in Heavily Refractory Myeloma

Tuesday, May 1st, 2018
In phase I trials, the first-in-class selective inhibitor of XPO1 selinexor (with or without low-dose dexamethasone) showed clinical activity against several types of hematologic...

Standardized MRD Assay for FLT3-ITD-Mutated AML Could Guide AML Therapy Decisions

Tuesday, May 1st, 2018
In a report published in Blood Advances, researchers describe a standardized minimal residual disease (MRD) assay that can detect FLT3-ITD mutations in patients with...
WIB_icon

International Workshop on CLL Updates Guidelines for the Design and Conduct of Clinical Trials

Tuesday, May 1st, 2018
Prompted by advances in the biology and treatment of patients with chronic lymphocytic leukemia (CLL), the National Cancer Institute–sponsored International Workshop on CLL has...
WIB_icon

Insights From a Pyruvate Kinase Deficiency Registry: Broad Spectrum of Severity, Broad Role for...

Tuesday, May 1st, 2018
No guidelines exist for the diagnosis, management, and monitoring of patients with red cell pyruvate kinase (PK) deficiency – the most common glycolytic defect...

ASCO Updates Platelet Transfusion Guidelines for Patients With Cancer

Tuesday, May 1st, 2018
ASCO Updates Platelet Transfusion Guidelines for Patients With Cancer Adult patients undergoing hematopoietic cell transplantation (HCT) can safely delay platelet transfusion until the first sign...

Brentuximab Vedotin Approved for Classical Hodgkin Lymphoma

Tuesday, May 1st, 2018
The FDA expanded the approval of brentuximab vedotin to include the treatment of adult patients with previously untreated stage III or IV classical Hodgkin...
WIB_icon

Brentuximab Vedotin and CHP Combination Leads to Lasting Remissions in Peripheral T-Cell Lymphomas

Tuesday, May 1st, 2018
Half of patients with peripheral T-cell lymphomas (PTCLs) who were treated with brentuximab vedotin in combination with CHP (cyclophosphamide, doxorubicin, prednisone) remained in remission...

SHARE